富士フイルム：iPS細胞の特許を供与：Lonza Walkersville, Inc.（動画）：
FUJIFILM: Granted iPS cell patent to the outside: Lonza Walkersville：
富士胶片：向外部授予iPS单元专利：Lonza Walkersville，Inc.。
富士フイルム：
FUJIFILM Cellular Dynamics：
米子会社がiPS細胞の特許を保持しています。
「医薬品候補物質の安全性や有効性を試験するためのiPS細胞」を販売中。
iPS細胞の作製：
iPS細胞の作製方法は複数あるが、富士フイルムの特許技術は安全性が高いとされる。
また治療用iPS細胞を作製できるのは数社・団体に限られる。
富士フイルムは、これまで「治療用iPS細胞の販売や特許供与」は、資本関係のある企業に限ってきた。
特許ライセンスを供与：
このほど外部に特許ライセンスを供与することを決め、第1弾としてロンザの米子会社に使用を許諾した。
再生医療製品の開発を対象に、治療用iPS細胞の作製に関する特許を供与する。
富士フイルムはロンザからライセンス収入を得るが、額は非公表。
ロンザの他にも「十数社から引き合いが来ている」（富士フイルム）という。
治療用iPS細胞の外販：
治療用iPS細胞の外販も始める。
iPS細胞を使った再生医療製品は、血液がんや骨髄移植の合併症向けで臨床試験（治験）が進むものの、実用化されていない。
米BCCリサーチ：
iPS細胞の世界市場は、2019年の24億ドルから、2024年には38億ドルに拡大する見込み。
富士フイルムは、「写真フィルムで培ったコラーゲンの技術」を、細胞培養に生かし、再生医療分野に参入した。
iPS細胞の外販や特許供与、製造受託などに注力する方針。
再生医療製品の製造受託：
2020年3月、米国で治療用iPS細胞の生産施設を稼働した。
将来は、iPS細胞を使った再生医療製品の製造受託で、世界首位を目指す。
日本経済新聞
https://www.nikkei.com/article/DGXMZO66135010S0A111C2XB0000/
FUJIFILM Cellular Dynamics and Lonza agree to expand the availability and use of induced pluripotent stem cell technology
FUJIFILM Cellular Dynamics and Lonza
agree to expand the availability and use of induced pluripotent stem cell technology – FUJIFILM Cellular Dynamics grants Lonza
a non-exclusive right to use their patents related to iPSC generation,
including episomal vectors and reprogramming factors, for development and clinical manufacture of iPSC lines for cell therapies
– Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology –
The agreement enables drug developers
to leverage both companies expertise and technologies for the generation of human-induced pluripotent stem cells through licensing agreements MADISON, Wis., and WALKERSVILLE, Md.,
November , 2020 — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Lonza Walkersville, Inc. (Lonza, a leading global GMP iPSC manufacturer),
have entered into a worldwide agreement. The agreement enables drug developers to leverage both companies’ expertise and technologies for the generation of iPSCs through licensing agreements.
Under the agreement,
FUJIFILM Cellular Dynamics
grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors, for the clinical manufacture and differentiation of iPSC lines for cell therapies.
Furthermore, Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology, to enable efficient transfection of cells, stem cell and cell lines.
Cell therapies
have emerged as a promising treatment modality with the ability to augment, repair, or replace human biology, including organs, tissues and cells.
Given their incredible capacity to self-renew and the ability to become many different cell types, iPSCs are a critical material used in the development and manufacture of cell therapies.
FUJIFILM Cellular Dynamics
is a key global player with the technology and expertise in iPSC episomal generation enabling high quality, purity and reproducibility,” said Takeshi Yamamoto, chief executive officer, FUJIFILM Cellular Dynamics.
We are pleased to reach this outcome with Lonza to produce iPSC lines to better serve drug developers.
We expect to grant additional patent licenses to pharmaceutical and biotech companies to support the growth of available cell therapies.
As true leaders in our field, both companies came to an agreement which benefits our customers and brings clarity to the industry.” said Alberto Santagostino, SVP, Head of Cell and Gene Technologies, Lonza.
It shows our common goal to make high quality iPSC therapies available at affordable cost to our customers.
Additionally, we are pleased to expand the license-use of our innovative Nucleofector™ technology granted to FUJIFILM Cellular Dynamics.
This agreement further strengthens our leading end-to-end proprietary service offering for iPSCs.
In combination with Lonza’s L7™ hPSC Culture System and non-viral 4D-Nucleofector™ Transfection Technology, this represents an excellent approach for reprogramming and culturing GMP grade iPSCs”
Fujifilm Global